|
O**I
发帖数: 776 | 2 【 以下文字转载自 pennystock 俱乐部 】
发信人: OSCI (TX), 信区: pennystock
标 题: FDA Drug Approvals in 2011
发信站: BBS 未名空间站 (Sat Jan 8 17:29:50 2011, 美东)
http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
... 阅读全帖 |
|
O**I
发帖数: 776 | 3 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
O**I
发帖数: 776 | 4 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
D******9
发帖数: 2665 | 5 They have only one drug, and the revenue is only 8 million.
Here is the news:
InterMune reported product revenue in the fourth quarter of 2011 of $7.8
million, consisting of $2.7 million from sales of Esbriet in Europe, and
Actimmune® (gamma interferon-1b) revenue of approximately $5.2 million.
Product sales in the fourth quarter 2010 consisted solely of $4.9 million
of Actimmune revenue, as the initial commercial launch of Esbriet was in
Germany in September 2011.
InterMune reported a ne... 阅读全帖 |
|
E***X
发帖数: 885 | 6 The MAA is the second major regulatory filing by InterMune to seek approval
to market pirfenidone for the treatment of patients with IPF. The New Drug
Application (NDA) for pirfenidone was filed by InterMune in the United
States in early November 2009. The U.S. Food and Drug Administration's (FDA)
Pulmonary-Allergy Drugs Advisory Committee (PADAC) is scheduled to discuss
the company's NDA for pirfenidone on March 9, 2010. Based on the
Prescription Drug User Fee Act (PDUFA), the FDA has set an ac |
|
|
w*******0
发帖数: 13 | 8 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
w*******0
发帖数: 13 | 9 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
E***X
发帖数: 885 | 10 Sell on news tomorrow?
Waterfall on rejection tomorrow?
Another leg up after approval tomorrow?
1. EXECUTIVE SUMMARY
1.1 Conclusions and Recommendations
InterMune, Inc. has proposed Esbriet® (pirfenidone) capsule for “the
treatment of patients with
idiopathic pulmonary fibrosis (IPF) to reduce decline in lung function.”
The information for the
proposed use of pirfenidone 2403 mg/d in IPF patients consists of the
efficacy and safety data
collected from Study 004 and Study 006.
Based on my co |
|
w****r
发帖数: 245 | 11 大侠，分类都分好了，求神签
# Basic Materials, Agricultural Chemicals
AGU Agrium Inc.
AVD American Vanguard Corp.
CAGC China Agritech Inc.
CF CF Industries Holdings, Inc.
CGA China Green Agriculture, Inc.
CMP Compass Minerals International
COIN Converted Organics Inc.
IPI Intrepid Potash, Inc.
MON Monsanto Co.
MOS Mosaic Co.
NOEC New Oriental Energy & Chemical
POT Potas... 阅读全帖 |
|
c*****l
发帖数: 739 | 12 坏消息 打压了不少
US InterMune to sell USD85m debt, 12.5m stock |
|
E*********r
发帖数: 4984 | 13 医药股上上下下太快，不好掌握入点。我们这里的一家做疫苗的Intermune， 开始那会
儿涨得很好，结果某一天，一个试验结果不好，当天股价折85%。 |
|
E*********r
发帖数: 4984 | 14 是这样的， 偶说过，以前这边的Intermune风光一时，股价绿翻天。一次实验失败，当
天股价打两折，跌80%。 现在就不死不活地呆着吧！ |
|
j***u
发帖数: 836 | 15 NEW YORK (TheStreet) -- InterMune ITMN soared to a 52-week high of $73.19 on
Monday after Swiss-based company Roche Holding announced it would buy the
biotechnology company for $8.3 billion.
Roche will pay $74 a share, which represents a 38% premium to Friday's
closing price of $53.80, in an all-cash deal.
奶子癌PBYI再爆8% |
|
j****n
发帖数: 4358 | 16 药企主要在New Jersey 和Boston, sf 没多少，今年onyx 裁员和intermune裁员，很多
人几个月都找不
到工作。
OFFICE. |
|
|
t*******o
发帖数: 1464 | 18 Oct. 30-Nov. 4
The American Association for the Study of Liver Disease convenes in Boston.
This is the most important meeting for hepatitis C drug research held on the
U.S. every year. Stocks to watch include Vertex Pharmaceuticals(TICKER
Quote)(VRTX Quote), InterMune(ITMN Quote), Pharmasset(VRUS Quote), Idenix
Pharmaceuticals(IDIX Quote) and Anadys Pharmaceuticals(ANDS Quote).
http://www.thestreet.com/story/10604926/2/biotech-calendar-key-dates-and-events.html
ANDS / IDIX 从三月份以来还没怎么涨过。如果这两个礼拜图形... 阅读全帖 |
|
h***e
发帖数: 7320 | 19 我们开个主题，肥猪和哈密我每天更新，希望大家能找到好匹克
如果大家发现新的event, 也请及时跟帖update，非常感谢 :)
Event Thread 不是推荐股票，欢迎讨论。
先给大家总结10月份的，以后每月开一贴哈
====================================
发信人: justsing (飞天的猪), 信区: pennystock
标 题: Re: 【Biotech Event Thread】
发信站: BBS 未名空间站 (Thu Oct 15 22:23:05 2009, 美东)
potentially stock-moving biotech events for October:
Oct. 5-6
JMP Securities Healthcare Focus conference
Oct. 7-8
Cowen & Co. 12 th Annual Therapeutics Conference
Oct. 8
FDA approval decision date for Spectrum Pharmaceuticals'(SPPI Quo... 阅读全帖 |
|
p**********r
发帖数: 108 | 20 ☆─────────────────────────────────────☆
pray2008 (stock888) 于 (Sun Apr 11 22:47:41 2010, 美东) 提到:
http://gwestrookitraders.com/fdadates.html
☆─────────────────────────────────────☆
tanmaomao (坛猫猫) 于 (Mon Apr 12 10:03:52 2010, 美东) 提到:
Biotech Stocks Facing FDA Approval From April - October 2010
Cell Therapeutics (CTIC)
Drug/indication: Pixantrone for non-Hod1gkin's lymphoma
Approval decision date: April 23
An FDA advisory panel held on March 22 voted 9-0 to recommend against
approval of ... 阅读全帖 |
|
g******0
发帖数: 1165 | 21 Posted: 3/13/10 09:32
I will list all these targets mentioned by news:
Their top five candidates, based on their takeout target rankings, include
Vertex Pharmaceuticals (VRTX), as the Massachusetts-based company is close
to commercializing telaprevir, a potential blockbuster treatment for
hepatitis C.
“The company is building a diversified portfolio,” says Migliore. “The
company has no drugs on the market, and it has never been profitable. But it
has an $8 billion market cap because investors ar... 阅读全帖 |
|
g******0
发帖数: 1165 | 22 发信人: gucci320 (Cigdog), 信区: pennystock
标 题: 转个老帖~潜在被收购的医药公司名单-（希望大家发现宝藏）
发信站: BBS 未名空间站 (Thu May 6 10:58:19 2010, 美东)
Posted: 3/13/10 09:32
I will list all these targets mentioned by news:
Their top five candidates, based on their takeout target rankings, include
Vertex Pharmaceuticals (VRTX), as the Massachusetts-based company is close
to commercializing telaprevir, a potential blockbuster treatment for
hepatitis C.
“The company is building a diversified portfolio,” says Migliore. “The
compan... 阅读全帖 |
|
t*******o
发帖数: 1464 | 23 这个股绝对值得关注，trial 3 so far不错。
目前这个领域的旗舰在研药， market potential巨大，而且下半年又有FDA event。
如果下半年FDA气氛好，肝病sector 的小bio也都有联动空间
hepatitis C drug research InterMune(ITMN Quote), Pharmasset(VRUS Quote),
Idenix，Pharmaceuticals(IDIX Quote) and Anadys Pharmaceuticals(ANDS Quote). |
|
y*****l
发帖数: 5997 | 24 股票:ARNA, VRTX, ATHX, BDSI, CTIC, BCRX, SGEN
http://finviz.com/screener.ashx?v=341&t=ARNA,VRTX,ATHX,BDSI,CTIC,BCRX,SGEN
http://www.thestreet.com/story/10849406/1/biotech-calendar-key-dates-for-september.html
To prepare, here is a calendar of important, potentially stock-moving
biotech events in September:
Phase III or pivotal registration studies that could report results in
September:
* Vertex Pharmaceuticals'(VRTX) hepatitis C drug telaprevir (previously
treated patients.)
* Seattle Gen... 阅读全帖 |
|
v**********m
发帖数: 5516 | 25 You guys now are able to listen to these web-castings now. Enjoy it!
http://jpmorgan.metameetings.com/webcasts/healthcare11/ondemand
individual Company Presentations
A
Abbott
Abiomed Inc. (available to Feb. 5)
Ablynx N.V.
Accretive Health Inc.
Accuray Inc.
Acorda Therapeutics, Inc. (available to Feb. 11)
Actelion Ltd
Aetna Inc. (available to Feb. 8)
Affymetrix Inc.
Agilent Technologies Inc.
Albany Molecular Research Inc.
Alere Inc (available to Feb. 11)
Alexion Pharmaceuticals, Inc. (not availab... 阅读全帖 |
|
v**********m
发帖数: 5516 | 26 You guys now are able to listen to these web-castings now. Enjoy it!
http://jpmorgan.metameetings.com/webcasts/healthcare11/ondemand
individual Company Presentations
A
Abbott
Abiomed Inc. (available to Feb. 5)
Ablynx N.V.
Accretive Health Inc.
Accuray Inc.
Acorda Therapeutics, Inc. (available to Feb. 11)
Actelion Ltd
Aetna Inc. (available to Feb. 8)
Affymetrix Inc.
Agilent Technologies Inc.
Albany Molecular Research Inc.
Alere Inc (available to Feb. 11)
Alexion Pharmaceuticals, Inc. (not availab... 阅读全帖 |
|
|
